The effect of exacerbation history on outcomes in the IMPACT trial

IMPACT, a 52-week, randomised, double-blind trial, assessed the efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI or UMEC/VI in patients with symptomatic COPD and a history of exacerbations. Subgroup analyses assessed whether the efficacy of...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur Respir J
Main Authors: Halpin, David M.G., Dransfield, Mark T., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, Lange, Peter, Lipson, David A., Lomas, David A., Martinez, Fernando J., Pascoe, Steve, Singh, Dave, Wise, Robert, Criner, Gerard J.
Format: Artigo
Sprog:Inglês
Udgivet: European Respiratory Society 2020
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286387/
https://ncbi.nlm.nih.gov/pubmed/32299860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.01921-2019
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker